United States Precision Medicine Industry New Product Launches in Q2 2025 | Major key Players- F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., AstraZeneca

The Global Precision Medicine Market size reached US$98.87 billion in 2024 and is expected to reach US$329.73 billion by 2033, growing at a CAGR of 14.8% during the forecast period of 2025-2033, according to DataM Intelligence report.

DataM Intelligence has published a new research report on "Precision Medicine Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/precision-medicine-market?oppratik

Major Precision Medicine M&A Deals in 2025:-

-Roche to Acquire 89bio: Roche will buy 89bio for approximately $3.5 billion, adding a Phase 3-ready therapy for metabolic dysfunction-associated steatohepatitis (MASH) to its pipeline. This strengthens Roche's position in precision therapies for emerging metabolic indications.​

-Novartis to Acquire Tourmaline Bio: Novartis is acquiring Tourmaline Bio for $1.5 billion, bringing in an anti-IL-6 antibody for cardiovascular and immune disorders. The deal is part of Novartis's push into targeted therapies with validated clinical pathways.​

-Genmab to Acquire Merus: Genmab is set to buy Merus for $1.8 billion, gaining a late-stage bispecific antibody platform for cancer immunotherapy. This acquisition enhances Genmab's portfolio of precision oncology assets.​

-VectorY and Shape Therapeutics: VectorY signed a $1.2 billion collaboration with Shape Therapeutics to develop gene therapies for neurological diseases. The deal focuses on novel delivery systems and crossing the blood-brain barrier with precision treatments.​

-Biogen Acquires Alcyone Therapeutics: Biogen bought Alcyone Therapeutics for $85 million, securing a specialized device for targeted spinal cord drug delivery-advancing therapies for neurological diseases.​

-Johnson & Johnson Acquires Intra-Cellular Therapies: J&J completed a $14.6 billion acquisition of Intra-Cellular Therapies, gaining Caplyta®, a precision neuropsychiatric therapy for schizophrenia and bipolar depression.

United States: Recent Product Launches:-

-❇️AI-Powered Genomic Diagnostic Platforms: Several US companies, including Danaher in partnership with AstraZeneca, introduced AI-driven diagnostic tools that enhance precision medicine by enabling faster, more accurate molecular profiling and treatment selection.​

-❇️Cell and Gene Therapies Scaling: The US market continues to launch expanded CAR-T therapies and other gene editing treatments, moving beyond hematologic cancers to solid tumors and rare genetic diseases.​

-❇️Multi-Omics and Digital Biomarkers: New commercial products integrate genomic, proteomic, and metabolomic data with digital biomarkers via wearable sensors for personalized disease management and precision dosing.​

-❇️Genomic AI Innovations: Collaborations like Illumina and Tempus introduced AI-powered genomic tools aimed at accelerating diagnostic decisions and personalized healthcare strategies in oncology and chronic disease.

Japan: Recent Product Launches:-

-❇️Illumina TruSight Oncology Comprehensive Test: Approved by Japan's Ministry of Health in May 2025, this is a genomic profiling test analyzing DNA and RNA variants over 500 genes to guide precision cancer therapies, increasing access for Japanese clinicians.​

-❇️Liquid Biopsy Companion Diagnostic Test: A.D.A.M. Innovations and SOPHiA GENETICS partnered to develop a liquid biopsy companion diagnostic test in Japan, designed to enhance personalized oncology and expedite drug development approvals.​

-❇️Integration of Genomics and AI for Personalized Medicine: Japanese companies are launching new AI-integrated services that combine genomic data with clinical insights, aiming to revolutionize patient care and health system efficiency.​

-❇️Emerging Precision Therapies & Research Collaborations: Japan is actively launching trials evaluating novel dual-inhibition drugs for genetically defined subsets of cancers, reflecting the growing precision medicine clinical landscape

FDA Approvals and Regulatory Updates (2025):-

-The FDA approved several novel drugs in 2025, focusing on precision medicine in oncology and rare diseases, including targeted therapies and biomarker-driven immunotherapies.

-Key oncology approvals in H1 2025 featured antibody-drug conjugates, small molecule targeted agents, and treatments for rare cancers like KRAS-mutated ovarian cancer and neurofibromatosis type 1.

-Regulatory frameworks are evolving to support AI/ML-based medical software, with updated guidance expected to streamline approvals for adaptive AI diagnostics and digital health tools.

-Performance-based payment models for gene and cell therapies are emerging, linking reimbursement to patient outcomes to improve accessibility and affordability.

Key players:-

F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., AstraZeneca, Pfizer Inc., GSK plc, Biogen, Bristol-Myers Squibb Company, Abbott, Merck & Co., Inc., and BGI, among others.

Growth Forecast Projected:

The Global Precision Medicine Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Precision Medicine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=precision-medicine-market?oppratik

Key Segments:

By Technology:

➖Big Data Analytics: Utilized to analyze large biological datasets for insights in disease patterns and drug development.

➖Bioinformatics: Integrates biology and computational tools to interpret complex genetic and molecular data.

➖Gene Sequencing: Enables detailed mapping of genetic material to identify mutations and hereditary conditions.

➖Drug Discovery: Applies computational and analytical tools to accelerate the identification of new therapeutic compounds.

By Application:

➖Diagnostics: Used to detect and monitor diseases through advanced genomic and molecular analysis.

➖Therapeutics: Supports the development of personalized and targeted treatment solutions.

Recent Investments:-

-Venture capital and private equity are actively funding startups focused on AI-powered diagnostics, cell and gene therapy platforms, and companion diagnostics. Notable investments include collaborations between pharmaceutical companies and tech firms to accelerate precision therapy development.​

-Strategic partnerships and major biotech acquisitions continued intensively in 2025, with companies focusing on oncology, rare diseases, and chronic conditions, where precision medicine delivers tailored treatment benefits.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Precision Medicine producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Precision Medicine revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/precision-medicine-market?oppratik

Latest Industry News and Trends (2025):-

The precision diagnostics and medicine market size is forecasted to expand from USD 143 billion in 2025 to USD 448.4 billion by 2034, showing strong CAGR (around 13.5%-16.35%) fueled by technology advancements and patient demand for more personalized care.​

Cutting-edge advancements in genomics, proteomics, metabolomics, and AI-driven data analytics are reshaping the drug development pipeline and clinical diagnostic offerings.​

Digital health ecosystems, including telehealth and wearable biosensors, are increasingly integrated into precision medicine strategies, enhancing patient monitoring and therapy adjustments.​

Oncology remains the dominant application segment, with growing focus on rare diseases and genetic disorders. North America leads the market share, followed by fast-growing Asia-Pacific regions

FAQ's

Q1: What is the current size of the Precision Medicine Market?

A: The Precision Medicine Market stood at US$98.87 billion in 2024 and is set to experience remarkable growth, reaching US$329.73 billion by 2033

Q2: How fast is the Precision Medicine Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 14.8% from 2025 to 2033

Q3: Which regions are dominating the Precision Medicine Market and which are fastest-growing?

A: North America dominating the Precision Medicine market.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/precision-medicine-market

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.